INTRODUCTION
Artemether is a drug used for the treatment of malaria [1, 2] . Artemether and lumefantrine combination is a fixed dose artemisinin-based combination therapy (ACT) combining artemether, an artemisinin derivative, and lumefantrine, a synthetic antimalarial drug for the treatment of malaria [3, 4] . Artemether is a fast acting drug with a short half-life. Lumefantrine acts slowly and has a longer half-life. On oral administration, the plasma concentration of artemether reaches peak level after 2 h while the peak plasma concentration of lumefantrine is attained after 6 -8 h [ 5 ] .
The International Pharmacopoeia monograph of artemether and lumefantrine tablet does not include a dissolution test [6] . No common single dissolution test method for simultaneous dissolution testing of artemether and lumefantrine tablets has been reported in the literature although separate dissolution methods for artemether and lumefantrine have been developed [7] . Artemether is poorly soluble in water while lumefantrine is practically insoluble in water. In general, developing an appropriate single dissolution method of discriminatory nature to evaluate the dissolution release of poorly soluble drugs from dosage forms has been a lingering challenge. [8] [9] [10] [11] In the present study, a single dissolution test method for the dissolution release of artemether and lumefantrine which will be very useful for quality control of combination tablets has been designed and validated in terms of the discriminatory power of the dissolution test. The HPLC method used for analysis has been validated at our laboratory.
EXPERIMENTAL

Reagents and materials
The working standards of artemether (99.4 % purity) and lumefantrine (98.3 % purity) were obtained from Micro Labs Ltd, India. Three reference products (A, B and C), each containing 20 mg of artemether and 120 mg of lumefantrine were obtained from Indian market. The test tablet product used was manufactured in-house. Water purified with Millipore Water Purification System (Elix 10 C model) was used for the preparation of buffers. Sodium acetate trihydrate, glacial acetic acid AR, potassium dihydrogen phosphate and sodium hydroxide pellets were sourced from Merck, India. PTFE membrane filters (0.45 µ, syringe filter25mm GD/X-Whatman) were used for filtration of standard and sample solutions. Cellulose acetate filter (0.45 µ, Sartorium stedim) was used for the filtration of the mobile phase.
Instrumentation
The dissolution test was carried out using an Electrolab Dissolution Test System (Model TDT-08L). A Waters HPLC system equipped with a 2695 solvent delivery system, Waters auto injector, thermostatted column compartment and Waters 2998 photo diode array detector was used. Waters Symmetry column (C-18 column of 250mm x 4.6mm i.d., 5 µ particle size) was used for the analysis.
Determination of solubility of artemether and lumefantrine
The solubility of artemether and lumefantrine was determined in the various dissolution media as follows. Artemether (500 mg) and lumefantrine (500 mg) were transferred into separate 100 ml conical flasks. Dissolution medium (50 ml) was added to each flask and the flasks were closed with Teflon-lined screw caps. These flasks were sonicated for 2 h at 37 °C with intermittent shaking. The solutions were each filtered, through a 0.45 µ Whatman membrane filter. Each filtrate was analysed separately by HPLC to determine the solubility of the drug in the particular dissolution medium.
Evaluation of stability of the drug solutions
The stability of artemether and lumefantrine in different dissolution media was evaluated at room temperature by calculating the change in peak area of samples at different time points which was then compared with that of the same sample immediately after injection.
Stirring rate and dissolution medium
Dissolution experiments were performed using standard USP dissolution apparatus 1 (basket) and apparatus 2 (paddle). Stirring rates of 100 rpm for basket, and 50, 75 and 100 rpm for paddle were evaluated. All the dissolution media used were de-aerated by sonication followed by filtration using membrane filter under vacuum.
Sample preparation and determination
The dissolution test was carried out using 1, 1.5 and 2 %w/v of Myrj 52 (polyoxyl 40 stearate) in 0.005M hydrochloric acid. Sample aliquots of 5.0 ml were withdrawn at different time points up to 120 min. After each withdrawal, a volume of dissolution medium equal to the volume of sample withdrawn was added to each vessel to maintain the volume in each vessel. The samples were filtered and analysed by HPLC and the percent drug release at each dissolution time point calculated.
Selection of sample filtration procedure
The filtration procedure for standard and sample solutions was evaluated using 2.5 µ pore filter paper (Whatman), 0.45 µ PTFE syringe filter (Whatman) and 0.45 µ nylon syringe filter (Advanced Microdevices, India)
Discriminatory power
The discriminatory power of the dissolution test was evaluated by (a) comparison of the dissolution results of reference products A, B, C and in-house test product (b) comparison of the dissolution results of in-house test product of various hardness (c) comparison of test results of the test products stored at 40 ºC and 75% RH with those of the test products stored at room temperature and humidity (23 °C / 60% RH)
Chromatographic conditions
The dissolution samples were analysed using Waters HPLC system, Symmetry column (C-18 column of 250mm x 4.6mm i.d., 5 µ particle size) with a mobile phase of a mixture of buffer and acetonitrile (20:80, v/v) at a flow rate of 1.0 ml/min. The buffer for mobile phase was prepared by diluting 5 ml of triethylamine to 1000 ml with water and adjusting the pH to 3.0 ± 0.05 using orthophosphoric acid. The detection wavelength was set at 216 nm and 100 µl of each sample was injected.
Preparation of lumefantrine standard stock solution
About 240 mg of lumefantrine working standard was accurately weighed and transferred into a 100 ml volumetric flask. About 25 ml of mobile phase and one drop of orthophosphoric acid were added, the solution sonicated to dissolve the drug and the volume made up to 100 ml with mobile phase.
Artemether standard stock solution
About 20 mg of artemether working standard was accurately weighed and transferred into a 100 ml volumetric flask. About 5 ml of acetonitrile was added and the solution was sonicated to dissolve the substance; the volume was then made up to 100 ml with dissolution medium.
Standard solution
Lumefantrine standard stock solution (5 ml) and 10 ml of artemether standard stock solution were transferred into a 100 ml volumetric flask and made up to volume with dissolution medium to obtain a concentration of 120 µg of lumefantrine and 20 µg of artemether per ml. This solution was filtered through 0.45 µ PTFE membrane filter (Whatman) and the filtrate used as standard solution.
Sample solution
During the dissolution test, 5 ml aliquots were withdrawn from the dissolution medium at various time points up to 120 min and replaced with an equal volume of fresh dissolution medium after each withdrawal to maintain a constant volume of the dissolution medium in the vessel. The samples were filtered through 0.45 µ PTFE membrane filter (Whatman) and the filtrate used as sample solution.
System suitability parameters
System suitability parameters of not less than 5.0 resolution between artemether and lumefantrine peaks, not more than 2.0 tailing factor for each peak, not less than 2000 theoretical plates for each peak and a %RSD of not more than 2.0 for five replicates of standard injection were specified as the system suitability requirements for the analytical method.
Method validation
The HPLC method was validated for specificity, linearity, precision, accuracy, filter validation, solution stability and robustness according to USP and ICH guidelines [12, 13] .
Statistical analysis
The dissolution values of the various formulations at different time points were compared using similarity factor (f2) and difference factor (f1) which were calculated using Eqs 1 and 2..
where R t and T t are the cumulative percentage dissolved at each of the selected 'n' time points of the reference and test product respectively 
RESULTS
The solubility and stability data for artemether and lumefantrine in various commonly used dissolution media are presented in Tables 1  and 2 on the basis of which the most suitable dissolution medium was selected.
The dissolution values of reference product A in 0.005M HCl containing 1.0, 1.5 and 2.0% w/v of Myrj 52 are presented in Table 3 while those of the reference products A, B, C and the test product in the selected dissolution medium of 2% w/v Myrj 52 in 0.005N hydrochloric acid at various time points are presented in Table 4 . The dissolution results of a formulation at a particular time point were different from those of other formulations at the same time point as per the Mann-Whitney U test. The difference factor (f1) values for the various formulations indicate significant difference in the release pattern of the formulations when compared with reference product A.
Validation of the HPLC method
The validation results for the HPLC method used for the determination of drug release are as follows.
Accuracy
The accuracy of the method in the range of 25 to 150 % of test concentration of artemether (20 µg/ml of artemether) and lumefantrine (120 µg/ml of lumefantrine) was satisfactory. Recovery (% was between 98.52 to 99.49% for artemether and 98.48 to 99.73% for lumefantrine. 
Precision
The intra-day and inter-day precision, compared in terms of %RSD, were close to each other indicating satisfactory level of precision of the method. %RSD for intra-day precision was 1.33 and 1.51 for artemether and 1.23 and 1.33 for lumefantrine on first and second day of analysis, respectively while%RSD for inter-day precision was 1.37 for artemether and 1.27 for lumefantrine
Linearity
The analytical method was linear for artemether and lumefantrine in the concentration range of 5 -150 % of test concentration of the drugs. The test concentration of artemether was 20 µg/ml and that of lumefantrine 120 µg/ml . The regression analysis of the linearity data yielded correlation coefficient values above 0.9990 for each drug (see Table 5 ).
Specificity
The specificity of the method was ascertained from the absence of peaks in the chromatogram of the dissolution medium at the retention times of artemether (Rt = 8.03 min) and lumefantrine (Rt = 5.34 min) as well as from the purity angle values. For artemether, the purity angle was 0.849 and 0.824 while the purity threshold was 1.269 and 1.312 in standard and sample solutions, respectively. Similarly, for lumefantrine the purity angle was 1.656 and 1.632 while the purity threshold was 9.897 and 9.832 in 67.6 ± 2.5 69.3 ± 2.3 83.4 ± 1.9 100.7 ± 1.1 standard and sample solution, respectively. The purity angle value, being less than the purity threshold value, indicates that the peaks are spectrally pure in standard and sample solutions.
Filter validation
The filtration procedure for artemether and lumefantrine standard and sample solutions was evaluated using three different types of filters, namely, 0.45µ mdi nylon filter (A), 0.45µ Whatman PTFE (B) filter and No. 42 Whatman filter paper (C).
The centrifuged solutions of the standard and sample were compared with the filtered solutions in terms of % recovery. The percentage peak area difference between the centrifuged solutions and solutions filtered through filters A, B and C was less than 1 % indicating that loss during filtration is within the acceptable limits.
Stability of solution
The stability of standard and sample solutions was studied for 24 h at room temperature. The standard and sample solutions were stable in 2 %w/v Myrj 52 in 
DISCUSSION
The sink condition for artemether (a minimum solubility of 60 µg/ml) may be achieved in all the dissolution media listed in Table 1 where- . Using 2 %w/v Myrj 52 in 0.005M HCl with paddle at 100rpm, 95 % of artemether was released in 60 min from each of the reference products (A, B and C) whereas above 95 % of lumefantrine was released only around 120 min. Hence, with 2 %w/v Myrj 52 in 0.005M HCl as dissolution medium and with a stirring rate of 100 rpm with paddle, the suggested dissolution release acceptance limit would not be less than 85 % of artemether in 60 min and not less than 85 % of lumefantrine in 120 min. A single time point of not less than 85 % release of each drug in 120 min may be considered for quality control test. However, the in-house limit for a particular tablet formulation of artemether and lumefantrine ought to be fixed on the basis of its dissolution performance using the developed method.
The HPLC method used for the determination of dissolution release of artemether and lumefantrine from tablets were validated in terms of accuracy, precision, linearity, specificity, filter validation, solution stability and robustness. The results of validation showed that all the validation parameters are satisfactory. The peak areas of artemether and lumifantrine peaks were linear with respect to concentration. The correlation coefficient values of 0.9999 indicate excellent correlation between response (peak area) and concentration.
CONCLUSION
The proposed dissolution test method for artemether and lumefantrine in tablets provides sink condition and is able to satisfactorily discriminate drug release between formulations differing in terms of hardness, exposure to heat and moisture and composition of excipients. The analysis was carried out by a HPLC method which was validated. Hence the proposed dissolution method may be used as a single test method for the routine dissolution testing of tablets containing artemether and lumefantrine.
